Related Experiment Video
Updated: Apr 23, 2026
10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
1.7K
Current nanotechnological strategies for treating glaucoma.
Gagandeep Goyal1, Tarun Garg2, Goutam Rath1
1Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
Critical Reviews in Therapeutic Drug Carrier Systems
|October 2, 2014
Summary
Nanotechnology offers new hope for glaucoma treatment by overcoming drug delivery challenges in the eye. These advanced systems improve drug penetration and reduce elimination for more effective ocular therapies.
Area of Science:
- Ophthalmology
- Nanotechnology
- Pharmaceutics
Background:
- Glaucoma is a leading cause of blindness globally.
- Conventional ocular drug delivery faces significant anatomical and physiological barriers.
- Existing treatments often suffer from poor drug penetration and rapid elimination.
Purpose of the Study:
- To review the role of nanotechnology in developing novel drug delivery systems for glaucoma.
- To explore the potential of advanced materials for improved ocular therapy.
- To discuss future possibilities for effective glaucoma treatment using nanotechnology.
Main Methods:
- Review of recent literature on nanotechnology-based ocular drug delivery.
- Analysis of various nanocarriers including liposomes, nanoparticles, and nanosuspensions.
- Discussion of innovative delivery platforms like ocular inserts and contact lenses.
Main Results:
- Nanotechnology enables overcoming conventional drug delivery limitations in the eye.
- Various nanocarrier systems show promise for enhanced intraocular drug penetration.
- New materials offer potential for sustained drug release and improved patient compliance.
Conclusions:
- Nanotechnology is crucial for advancing glaucoma treatment strategies.
- Novel nanodelivery systems represent a significant step towards effective glaucoma management.
- Future research in nanotechnology holds great promise for preventing blindness due to glaucoma.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
01:23Ophthalmic Drug Delivery Systems
274
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
274